Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?   

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521.  Following prostatectomy, however, the SPCG12 abstract presented at ASCO 2016 seemed to indicate that docetaxel provided no benefit, though these patients did not recieve ADT. In your practice, are there patients to whom you offer adjuvant chemo (with or without androgen suppression) following prostatectomy?